Literature DB >> 9038759

Ki-67 expression in early prostate cancer and associated pathological lesions.

M R Feneley1, M P Young, C Chinyama, R S Kirby, M C Parkinson.   

Abstract

AIM: To assess cell proliferation in early prostate cancer and associated pathological lesions.
METHODS: Using the Ki-67 antibody, the cell proliferation index was measured in early stage prostatic carcinoma in 37 incidental tumours diagnosed at transurethral prostatectomy (TURP) and in 20 low volume cancers treated by radical prostatectomy. Proliferation indexes have also been measured in areas of normal peripheral zone, transition zone hyperplasia, atrophic appearing lobules, and high grade prostatic intraepithelial neoplasia in the radical prostatectomy cases.
RESULTS: In the TURP series the proliferation index correlated with grade and stage. Logistic regression analysis, however, showed that Gleason grade was the most reliable predictor of biopsy proven residual disease and clinical progression. In the radical series transition zone carcinoma the proliferation index was half that of peripheral zone carcinoma. The atrophic lobules also showed a high proliferation index of the same order as seen in the peripheral zone carcinoma. Normal peripheral zone showed the lowest proliferation index and in hyperplastic transition zone it was also less than the other areas.
CONCLUSIONS: There is only limited support for the correlation of proliferation index with grade in early stage prostatic carcinoma. The findings do not suggest that proliferation index adds to the prognostic information given by grade and stage in pT1 disease. The significant difference in proliferation index in transition zone and peripheral zone carcinomas supports the morphological distinction of these tumour types and is consistent with differences in biological behaviour. The high proliferation index in lobules considered morphologically atrophic is reminiscent of previous observations in which carcinoma was spatially associated with atrophy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9038759      PMCID: PMC500724          DOI: 10.1136/jcp.49.9.741

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  34 in total

1.  Which proliferation markers for routine immunohistology? A comparison of five antibodies.

Authors:  D S Rose; P H Maddox; D C Brown
Journal:  J Clin Pathol       Date:  1994-11       Impact factor: 3.411

2.  The proliferative function of basal cells in the normal and hyperplastic human prostate.

Authors:  H Bonkhoff; U Stein; K Remberger
Journal:  Prostate       Date:  1994       Impact factor: 4.104

3.  Peroxidase labelling immunocytochemistry: a comparison of eleven commercially-available avidin-biotin systems.

Authors:  L C Happerfield; L G Bobrow; R Bains; K D Miller
Journal:  Br J Biomed Sci       Date:  1993-03       Impact factor: 3.829

4.  Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues.

Authors:  A J Norton; S Jordan; P Yeomans
Journal:  J Pathol       Date:  1994-08       Impact factor: 7.996

5.  Prostatic intra-epithelial neoplasia: expression and location of proliferating cell nuclear antigen in epithelial, endothelial and stromal nuclei.

Authors:  R Montironi; C M Galluzzi; L Diamanti; I Giannulis; E Pisani; M Scarpelli
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

6.  Cell proliferation in prostatic adenocarcinoma: in vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression.

Authors:  P R Carroll; F M Waldman; W Rosenau; M B Cohen; J M Vapnek; P Fong; P Narayan; B H Mayall
Journal:  J Urol       Date:  1993-02       Impact factor: 7.450

Review 7.  Zonal origin of prostatic adenocarcinoma: are there biologic differences between transition zone and peripheral zone adenocarcinomas of the prostate gland?

Authors:  D J Grignon; W A Sakr
Journal:  J Cell Biochem Suppl       Date:  1994

8.  Post-operative serial prostate-specific antigen and transrectal ultrasound for staging incidental carcinoma of the prostate.

Authors:  M R Feneley; J A Webb; A McLean; R S Kirby
Journal:  Br J Urol       Date:  1995-01

9.  Numerical chromosomal aberrations in prostate cancer: correlation with morphology and cell kinetics.

Authors:  R P Henke; E Krüger; N Ayhan; D Hübner; P Hammerer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

Review 10.  Update on proliferation-associated antibodies applicable to formalin-fixed paraffin-embedded tissue and their clinical applications.

Authors:  C C Yu; M I Filipe
Journal:  Histochem J       Date:  1993-12
View more
  14 in total

1.  Synthesis of novel 4-Boc-piperidone chalcones and evaluation of their cytotoxic activity against highly-metastatic cancer cells.

Authors:  Carlimar Ocasio-Malavé; Metsiel J Donate; María M Sánchez; Jesús M Sosa-Rivera; Joseph W Mooney; Tomás A Pereles-De León; Néstor M Carballeira; Beatriz Zayas; Christian E Vélez-Gerena; Magaly Martínez-Ferrer; David J Sanabria-Ríos
Journal:  Bioorg Med Chem Lett       Date:  2019-10-28       Impact factor: 2.823

2.  Does screening for prostate cancer identify clinically important disease?

Authors:  M R Feneley
Journal:  Ann R Coll Surg Engl       Date:  1999-05       Impact factor: 1.891

3.  Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy.

Authors:  Geert J L H van Leenders; Wesley R Gage; Jessica L Hicks; Bianca van Balken; Tilly W Aalders; Jack A Schalken; Angelo M De Marzo
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

4.  Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage - impact of tissue environment.

Authors:  K R Keshari; H Tsachres; R Iman; L Delos Santos; Z L Tabatabai; K Shinohara; D B Vigneron; J Kurhanewicz
Journal:  NMR Biomed       Date:  2011-07       Impact factor: 4.044

5.  Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach.

Authors:  G de Pinieux; M E Legrier; F Poirson-Bichat; Y Courty; R Bras-Gonçalves; A M Dutrillaux; F Némati; S Oudard; R Lidereau; P Broqua; J L Junien; B Dutrillaux; M F Poupon
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

6.  Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer.

Authors:  Oleksandr N Kryvenko; Michelle Jankowski; Dhananjay A Chitale; Deliang Tang; Andrew Rundle; Sheri Trudeau; Benjamin A Rybicki
Journal:  Mod Pathol       Date:  2012-03-30       Impact factor: 7.842

Review 7.  Inflammation in prostate carcinogenesis.

Authors:  Angelo M De Marzo; Elizabeth A Platz; Siobhan Sutcliffe; Jianfeng Xu; Henrik Grönberg; Charles G Drake; Yasutomo Nakai; William B Isaacs; William G Nelson
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

Review 8.  Immunopathological prognostic and predictive factors in prostate cancer.

Authors:  E Sivridis; S Touloupidis; A Giatromanolaki
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

9.  Survival analysis of patients with biochemical relapse after radical prostatectomy treated with androgen deprivation: Castration-resistance influential factors.

Authors:  Rubén Algarra; Mateo Hevia; Antonio Tienza; Imanol Merino; José María Velis; Javier Zudaire; José Enrique Robles; Ignacio Pascual
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

Review 10.  Telomeres and telomerase in prostate cancer development and therapy.

Authors:  Mindy Kim Graham; Alan Meeker
Journal:  Nat Rev Urol       Date:  2017-07-04       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.